Samjin Pharmaceutical Signs Agreement with Aribio Lab for Joint Vaccine Development and Commercialization

Collaboration on the Development of Herpes Zoster and Hepatitis B Vaccines

Samjin Pharmaceutical announced on June 1 that it has signed a strategic memorandum of understanding (MOU) with Aribio Lab for the joint development and commercialization of vaccines for herpes zoster and hepatitis B.

From the left, Sangjin Kim, President of Samjin Pharmaceutical, and Jaejun Jung, CEO of Aribio Lab, are posing for a commemorative photo at the strategic business alliance signing ceremony. Samjin Pharmaceutical

The two companies plan to collaborate on vaccine development and commercialization by combining Aribio Lab's immune enhancement platform technology with Samjin Pharmaceutical's research and development, as well as sales and marketing capabilities.

Under this agreement, the companies will explore ways to cooperate in the domestic sales of the herpes zoster and hepatitis B vaccines currently being developed by Aribio Lab. They will also pursue joint research and development of vaccine pipelines utilizing the immune enhancement platform technologies 'L-pampo' and 'Lipo-pam'. Aribio Lab is currently conducting phase 2 clinical trials for its recombinant herpes zoster vaccine, 'CVI-VZV-001'.

Sangjin Kim, President of Samjin Pharmaceutical, stated, "By combining the research and development capabilities and commercialization expertise of both companies, we have established a foundation to create synergy in the vaccine field." Jaejun Jung, CEO of Aribio Lab, added, "Through the development of herpes zoster and hepatitis B vaccines, as well as next-generation immune enhancement technologies, we aim to strengthen the competitiveness of domestic vaccines."

This content was produced with the assistance of AI translation services.